Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer.
Ji-Bing Chen, Xiao-Feng Kong, Feng Mu, Tian-Yu Lu, You-Yong Lu, Ke-Cheng Xu · Medical gas research · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 20 patients with advanced non-small cell lung cancer, 45 the researchers found that the prevalence of insomnia, dizziness and headache could be reduced significantly after H₂ inhalation, which could be related to relief of diseases of the central nervous system, such as cerebral hemorrhage, 46 47 48 Parkinson's disease 49 50 and Alzheimer's disease, 51 52 observed in animal experiments. These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 20 patients with advanced non-small cell lung cancer. 45 the researchers found that the prevalence of insomnia, dizziness and headache could be reduced significantly after H₂ inhalation, which could be related to relief of diseases of the central nervous system, such as cerebral hemorrhage, 46 47 48 Parkinson's disease 49 50 and Alzheimer's disease, 51 52 observed in animal experiments.
What the Researchers Studied
The researchers studied 20 patients with advanced non-small cell lung cancer. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 66.7% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 66.7% source-reported H₂ gas concentration; reported treatment duration: 5 months. 45 the researchers found that the prevalence of insomnia, dizziness and headache could be reduced significantly after H₂ inhalation, which could be related to relief of diseases of the central nervous system, such as cerebral hemorrhage, 46 47 48 Parkinson's disease 49 50 and Alzheimer's disease, 51 52 observed in animal experiments.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 20 patients with advanced non-small cell lung cancer. The reported sample size was 8. The study used a randomized human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 66.7% source-reported H₂ gas concentration. The reported treatment duration was 5 months.
Limitations and Safety
Reported limitations: The main limitation of this study is that the number of patients enrolled is relatively small, and more accurate patient benefits are still awaiting the results of large samples.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.